Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vistagen Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $0.41 Mil. Vistagen Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $86.63 Mil. Therefore, Vistagen Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.
Asset Turnover is linked to ROE % through Du Pont Formula. Vistagen Therapeutics's annualizedROE % for the quarter that ended in Dec. 2023 was -31.96%. It is also linked to ROA % through Du Pont Formula. Vistagen Therapeutics's annualizedROA % for the quarter that ended in Dec. 2023 was -29.32%.
Vistagen Therapeutics Asset Turnover Historical Data
The historical data trend for Vistagen Therapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vistagen Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics Asset Turnover Distribution
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's Asset Turnover falls into.
Vistagen Therapeutics Asset Turnover Calculation
Asset Turnover measures how quickly a company turns over its asset through sales.
Vistagen Therapeutics's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Vistagen Therapeutics's annulizedROA % for the quarter that ended in Dec. 2023 is
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Vistagen Therapeutics Asset Turnover Related Terms
Thank you for viewing the detailed overview of Vistagen Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your 